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Abstract
Findings: At first 32 housekeeping genes were analyzed in six randomly chosen meningiomas, brain and dura
mater using geNorm, NormFinder, Bestkeeper-1 software and the comparative ΔCt method. Reference genes were
ranked according to an integration tool for analyzing reference genes expression based on those four algorithms.
Eight highest ranked reference genes (CASC3, EIF2B1, IPO8, MRPL19, PGK1, POP4, PPIA, and RPL37A) plus GAPDH
and ACTB were then analyzed in 35 meningiomas, arachnoidea, dura mater and normal brain. NormFinder and
Bestkeeper-1 identified RPL37A as the most stable expressed gene in meningiomas and their normal control tissue.
NormFinder also determined the best combination of genes: RPL37A and EIF2B1. Commonly used reference genes
GAPDH and ACTB were considered least stable genes. The critical influence of reference genes on qPCR data
analysis is shown for VEGFA transcription patterns.
Background: In meningiomas quantitative real-time reverse transcription-polymerase chain reaction (qPCR) is most
frequently used for accurate determination of gene expression using various reference genes. Although
meningiomas are a heterogeneous group of tissue, no data have been reported to validate reference genes for
meningiomas and their control tissues.
Conclusions: RPL37A is the optimal single reference gene for normalization of gene expression in meningiomas
and their control tissues, although the use of the combination of RPL37A and EIF2B1 would provide more stable
results.
Background
Meningiomas are the most frequent intracranial tumours.
They originate from the arachnoidal cap cells of the
meningeal coverings of the spinal cord and brain, consti-
tuting for approximatively 13 to 26% of all intracranial
pathologies [1,2]. The conventional strategy for meningio-
mas is surgery [3,4]. However, some meningiomas recur as
resection might be sub totally due to their delicate location
at skull-based structures. The definition of malignant
potential is beset by the frequent discordance between his-
tology and biology [5,6]. Meningiomas are categorized in
three WHO grades, in which there are several subtypes
differentiated by their histological features.
Real-time quantitative reverse transcription polymerase
chain reaction (RT-qPCR) is a sensitive and reliable
method for quantifying gene expression. Most frequently
the relative quantification method is used, which requires
the use of an internal control gene for normalization.
Reference genes are mostly genes, which are involved in
basic metabolism and maintenance of the cell. An ideal
reference gene should be expressed at a constant level in
all examined tissues and cells, and should not be influ-
enced by experimental conditions. However several studies
have shown, that genes used as reference gene display sig-
nificantly different gene expression levels [7-9].
Established housekeeping genes in meningioma RT-
qPCR experiments are genes such as glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and b-Actin (ACTB)
[10-18] as well as ribosomal RNA (18S rRNA) and TATA
binding box protein (TBP) [19-21]. As the application of
these various housekeeping genes shows, there are no
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were validated. Due to the heterogeneity of meningioma
tissue and the necessity to compare meningiomas and
their control tissue reliably, the selection of an appropriate
reference gene with stable gene expression throughout the
various tissues is essential for further use of RT-qPCR in
meningioma research.
In this study, we investigate the gene expression levels
of 32 commonly used housekeeping genes in meningio-
mas and their control tissues arachnoidea, dura and nor-
mal brain. The RT-qPCR results were analyzed with
four different algorithms, to select eight suitable refer-
ence genes. Those genes plus GAPDH and ACTB were
compared in an increased number of meningiomas and
control tissues. These RT-qPCR results were further
analyzed with two different algorithms: NormFinder and
Bestkeeper-1.
Methods
Tumour Specimens and Cell Culture
Meningioma surgical specimens as well as arachnoidea
and dura mater were obtained from the Neurosurgical
Department in accordance to regulations of the Ethic
Committee of the University of Tuebingen. Primary cul-
tures were obtained from tumour tissue samples within 30
minutes of surgical removal. Samples were first washed in
phosphate-buffered saline (PBS), reduced and mashed
through a filter and placed in Dulbecco’s modified Eagle’s
medium (DMEM) with fetal bovine serum (FBS), 2 mmol/
L L-glutamine and 0,1% 10 mg/ml Gentamicin (Invitro-
gen, Grand Island, NY). Cells were plated in 25-mm
2 tis-
sue culture flasks and incubated at 37°C in a humidified
atmosphere of 5% CO2. Medium was changed every 3 to 4
days and cultures were split using 600 μl Accutase (PAA,
Pasching; Austria). Viable cells were stored in liquid nitro-
gen in 90% medium/10% dimethyl sulfoxide.
RNA isolation and reverse transcription
Meningioma total ribonucleic acid (RNA) was isolated
directly from primary cell cultures before splitting and
RNA of Arachnoidea and dura was isolated from fresh tis-
sue using PARIS
® kit (Ambion, Inc., Austin, TX), accord-
ing to the manufacturer’s protocol. RNA was treated with
DNA-free™ (Ambion, Inc., Austin, TX) to remove resi-
dual genomic DNA. The concentration of the isolated
RNA and the 260/280 absorbance ratio was measured in
triplicates with Eppendorf Biophotometer (Eppendorf,
Hamburg, Germany). The integrity of RNA samples was
confirmed by electrophoresis on a 2% Sybr Green agarose
gel (Invitrogen Inc., Carlsbad, CA). The criterion to
include RNA samples was 260/280 ~ 2 (1.9 to 2.2) and
28S/18S ratio ≥ 1.7. The probes were stored at - 80°C until
use. For normal brain FirstChoice
® Human Brain Refer-
ence RNA (Ambion, Inc., Austin, TX) was used, which
pools RNA from different donors and several brain
regions. RNA samples were DNase treated using DNAfree
kit (Ambion Inc., Austin, TX). Total RNA (1 μg) was
reverse-transcribed to cDNA using des High Capacity
RNA-to-cDNA Kits (Applied Biosystems, Foster City, CA)
in a total volume of 20 μl, according to the manufacturer’s
protocol.
Primer selection
For investigation to identify the most stable reference
gene that could be used for normalization in RT-qPCR
studies in meningiomas TaqMan
® Express Plate Human
Endogenous Control Plates (Applied Biosystems, Foster
City, CA) were used, which contained 32 different genes
plated in triplicates (Table 1). This collection of genes
has been selected from literature searches and/or whole
genome microarray tests carried out on numerous
human tissues. They have been shown to be expressed
constitutively and at moderate abundance across most
test samples. All primers further evaluated spanned an
exon junction to minimize inaccuracies due to genomic
DNA contamination in RNA samples except the primer
for S18. Additional information on assay optimisation
and validation such as primer sequence for each Taq-
Man
® Assay are available from Applied Biosystems.
Priming conditions, primer concentration and annealing
temperature was identical in all used TaqMan
® Gene
Expression Assays. TaqMan
®-based detection was cho-
sen, because this detection method detects only specific
amplification products, whereas SYBR
®-Green based
detection detects all amplified double-stranded DNA,
including nonspecific double-stranded DNA sequences,
which may generate false positive signals. Melt curves
were not assessed because they are only suitable for
SYBR
®-Green based detection.
For further evaluation single TaqMan
® Gene Expres-
sion Assays for ACTB, CASC3, EIF2B1, GAPDH, IPO8,
MRPL19, PGK1, POP4, PPIA, RPL37A (Applied Biosys-
tems, Foster City, CA) were used, which were identical
with the assays used in TaqMan
® Express Plate Human
Endogenous Control Plates.
Real-time PCR
TaqMan
® real-time PCR was run in triplicates in 48-well
reaction plates with a StepOne™ (Applied Biosystems,
Foster City, CA). Real-time PCR reaction was performed
with 1 μlc D N A( 5n g / μl) in 20 μl reaction mix contain-
ing 10 μlT a q M a n
® Gene Expression Master Mix
(Applied Biosystems, Foster City, CA) and 1 μl TaqMan
®
Gene Expression Assays (Applied Biosystems, Foster
City, CA). The cycling conditions were as follows: initial
holding period at 95°C for 10 min, followed by a two-step
PCR program consisting of 95°C for 15 s and 60°C for
1m i nf o r4 0c y c l e s .R e v e r s et r a n s c r i p t a s en e g a t i v e
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PCR) were included. Data were collected and quantita-
tively analyzed using StepOne™ Software v2.1. Relative
quantitation analysis of gene expression data for VEGFA
analysis was conducted according to the 2
-ΔΔCt method
[22].
For PCR efficiency a 5-fold dilution series was created
from a random pool of cDNA from our sample group ran-
ging from 50 ng to 0.08 ng. PCR were performed as
described above in triplicate. The PCR efficiency and
correlation coefficients (R
2) of each TaqMan
® Gene
Expression Assay were generated using the slops of the
standard curves. The efficiencies were calculated by the
formula: efficiency (%) = (10
(-1/slope) -1) * 100. All assays
displayed efficiencies between 93.2% and 100.2% (Table 2).
Statistical analysis
To compare the stability of candidate reference genes,
four validation software programs were used according
to their original publication: geNorm http://medgen.
ugent.be/~jvdesomp/genorm[23], NormFinder http://
www.mdl.dk/publicationsnormfinder.htm[24],
Table 1 Candidate reference genes evaluated in this study
Gene
Symbol
Gene Name Genbank Acession No. TaqMan
®Assay ID Amplicon
length
18S Eukaryotic 18S rRNA X03205.1 (mRNA) Hs99999901_s1 187
ABL1 v-abl Abelson murine leukemia oncogene homolog 1 NM_005157.3 + NM_007313.2 Hs00245445_m1 91
ACTB Actin, Beta, cytoplasmic NM_001101.3 Hs99999903_m1 171
B2M Beta-2-microglobulin NM_004048.2 Hs99999907_m1 75
CASC3 cancer susceptibility candidate 3 NM_007359.4 Hs00201226_m1 67
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) NM_078467.1 + NM_000389.3 Hs00355782_m1 66
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) NM_004064.3 Hs00153277_m1 71
EIF2B1 eukaryotic translation initiation factor 2B, subunit 1 alpha, 26
kDa
NM_001414.3 Hs00426752_m1 75
ELF1 E74-like factor 1/ets domain transcription factor) NM_172373.3 +
NM_001145353.1
Hs00152844_m1 76
GADD45A growth arrest and DNA-damage-inducible, alpha NM_001924.2 Hs00169255_m1 123
GAPDH Glyceraldehyde-3-phosphate dehydrogenase NM_002046.3 Hs99999905_m1 122
GUSB Glucuronidase, Beta NM_000181.3 Hs99999908_m1 81
HMBS Hydromethylbilane synthase NM_000190.3 Hs00609297_m1 64
HPRT1 Hypoxanthine guanine phospho- ribosyl transferase 1 NM_000194.2 Hs99999909_m1 100
IPO8 Improtin 8 NM_006390.2 Hs00183553_m1 71
MRPL19 mitochondrial ribosomal protein L19 NM_014763.3 Hs00608519_m1 72
MT-ATP6 mitochondrially encoded ATP synthase 6 NC_001807.ATP6.0 Hs02596862_g1 150
PES1 pescadillo homolog 1, containing BRCT domain (zebrafish) NM_014303.2 Hs00362795_g1 56
PGK1 Phosphoglycerate kinase 1 NM_000291.3 Hs99999906_m1 75
POLR2A Polymerase (RNA) II (DNA directed) polypeptide A, 220 kDa NM_000937.3 Hs00172181_m1 61
POP4 processing of precursor 4, ribonuclease P/MRP subunit NM_006627.2 Hs00198357_m1 68
PPIA Peptidylprolyl Isomerase A NM_021130.3 Hs99999904_m1 98
PSMC4 proteasome (prosome, macropain) 26S subunit, ATPase, 4 NM_153001.1 + NM_006503.2 Hs00197826_m1 83
PUM1 pumilio homolog 1 (Drosophila) NM_001020658.1 +
NM_014676.2
Hs00206469_m1 89
RPL30 ribosomal protein L30 NM_000989.2 Hs00265497_m1 149
RPL37A ribosomal protein L37A NM_000998.4 Hs01102345_m1 125
RPLP0 Ribosomal protein, large, P0 NM_053275.3 + NM_001002.3 Hs99999902_m1 105
RPS17 ribosomal protein S17 NM_001021.3 Hs00734303_g1 93
TBP TATA binding box protein NM_008907 Hs99999910_m1 127
TFRC Transferrin receptor NM_001128148.1 +
NM_003234.2
Hs99999911_m1 105
UBC Ubiquitin C NM_021009.4 Hs00824723_m1 71
YWHAZ Tyrosine 3-monooxygenase NM_003406.3 Hs00237047_m1 70
Thickly printed reference genes were further evaluated. TaqMan
® Assay ID ending with “_m” indicates an assay whose probe spans an exon junction and will not
detect genomic DNA. “_g” indicates an assay that may detect genomic DNA. The assay primers and probe may also be within a single exon. “_s” indicates an
assay whose primers and probes are designed within a single exon, such assays will, by definition detect genomic DNA. Additional information for each
TaqMan
® Assay is available from Applied Biosystems.
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keeper.html[25] and the comparative delta Ct method
[26]. For geNorm and NormFinder the raw Ct values
were transformed to quantities by using the delta Ct
method [27]. The highest relative quantities for each
gene were set to 1. Bestkeeper-1 and the comparative
delta Ct method use raw Ct values. To evaluate the
results from the four algorithms an integration tool for
analyzing reference genes expression was used http://
www.leonxie.com/referencegene.php. First according to
the reference genes ranking by every algorithm from the
most stable gene to the least stable gene, a series of con-
tinuous integers starting from 1 as weight to each refer-
ence gene is assigned. The geomean of each gene
weights across the four algorithms is calculated and
then these reference genes are re-ranked. The gene with
the less geomean is viewed as more stable reference
g e n e .I n p u td a t ai sv a l u ed a t af r o mR e a l - T i m eq R T -
PCR. Statistical analysis was performed with GraphPad
Prism V5.03 (GraphPad Software, La Jolla, USA). Nor-
mality was assessed according to D’Agostino-Pearson
tests with alpha = 0.05. For evaluation of statistical
equivalence a confidence-interval version of the Two
One-Sided Tests (TOST) procedure of Schuirmann was
used [28]. The groups are considered equivalent at a 5%
significance level if their difference has a 90% confidence
interval that lies entirely inside the upper and lower
equivalence limits. Therefore we considered ± δ = ± 1.5
to be reasonable limits of equivalence.
Results
Expression levels of 32 reference genes in meningioma
and normal tissue
To select suitable reference genes TaqMan
® human endo-
genous control plates (Applied Biosystems, Foster City,
CA, USA) were used containing 32 known housekeeping
genes (Table 1). Four different meningiomas, the malig-
nant meningioma cell line IOMM-Lee, normal brain, cere-
bral meninges and dura mater were analyzed regarding the
gene expression levels of those housekeeping genes. The
mean Ct values displayed a wide range of expression levels
between 10.41 and 33.78 as shown in Figure 1. The most
abundant transcript was S18 with median Ct value of
11.50 in meningiomas and a mean Ct value of 13.59 in
normal tissue. In meningioma the lowest expressed genes
were YHWAZ with median Ct value of 30.27 and TBP
with 30.08. In normal tissue HMBS had the lowest expres-
sion with a median Ct value of 32.70. Tumour tissue and
normal tissue group of five candidate reference genes
(CASC3, CDKN1B, POLR2A, PUM1 and UBC) were sta-
tistically equivalent to within ± 1.5.
Expression stability of 32 candidate reference genes in
meningioma and brain
All 32 housekeeping genes were analyzed using four dif-
ferent algorithms, geNorm NormFinder, Bestkeeper-2
and the comparative delta Ct method. An integration
tool calculated the geomean of each gene across the
four algorithms and ranked the reference genes accord-
ing to their comprehensive gene stability (Figure 2). The
three most stable reference genes were PGK1 > RPL37A
> POP4. The least stable reference genes were CDKN1A
> RPL0 > GADD45A. Three of four used algorithms
ranked PGK1 highest, only Bestkeeper-1 ranked CASC3
highest and PGK1 only in fourteenth place. For further
analysis eight of the highest ranked expression genes
were chosen: PGK1, RPL37A, POP4, MRPL19, IPO8
and CASC3. Additionally the most used reference genes
in meningioma qPCR experiments ACTB and GAPDH
were also chosen although being only ranked in fifteenth
respectively eighteens place and being considered incon-
sistent with a standard deviation (SD) higher than 1 by
Bestkeeper-1. Three reference genes (CDKN1B, UBC
and POLR2A) with equivalent tumour and normal tissue
group were ranked low from position 19 to 22 respec-
tively 13. CASC3 was the only one included for further
investigation with statistically equal groups.
Expression stability of eight reference genes plus GAPDH
and ACTB in meningiomas, arachnoidea, dura and normal
brain
To validate the expression stability of CASC3, EIF2B1,
IPO8, MRPL19, PGK1, POP4, PPIA, RPL37A plus
GAPDH and ACTB, thirty-four randomly chosen pri-
mary cultured meningiomas, the meningioma cell line
IOMM-Lee, two arachnoidea, six dura mater, one cer-
ebral meninges and two pooled normal brain samples
were screened for these reference genes. For analysis
two different algorithms were chosen: NormFinder
and Bestkeeper-1. NormFinder has a model-based
approach whereas Bestkeeper-1 employs a pair-wise
correlation analysis. NormFinder also estimates the
variation between subgroups such as normal and can-
cer tissue.
Table 2 Efficiency data for evaluated genes
Gene symbol Slope R
2 Efficiency (100%)
ACTB - 3.420 1.000 96.1
CASC3 - 3.442 0.999 95.2
EIF2B1 - 3.434 0.997 95.5
GAPDH - 3.430 1.000 95.7
IPO8 - 3.390 1.00 97.3
MRPL19 - 3.364 0.999 98.3
PGK1 - 3.266 0.994 100.2
POP4 - 3.410 0.999 96.4
PPIA - 3.497 1.00 93.2
RPL37A - 3.406 1.000 96.6
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gene in meningiomas and normal control tissue with an
average expression stability value (M) value of 0.54 (Best-
keeper-1) respectively 0.12 (NormFinder). NormFinder
not only determines the most stable gene, but also the
best combination of two genes, which are RPL73A and
EIF2B1 with a stability value of 0.088. The remaining
ranking differed significantly for Bestkeeper-1 and Norm-
Finder (Table 3). Bestkeeper-1 considered ACTB incon-
sistent with SD = 1.00 in meningiomas and their control
tissue, whereas PGK1 was inconsistent in meningiomas
(SD = 1.04). Both algorithms determined EIF2B1 and
RPL37A as the two most stable genes in normal tissue
(Table 5). In contrast there were significant differences
between the ranking of Bestkeeper-1 and NormFinder in
meningiomas (Table 4). Bestkeeper-1 ranked CASC3 and
RPL37A highest. NormFinder identified MRPL19 and
POP4 as the two most suitable genes, ranking CASC3
and RPL37A in eighth respectively ninth position.
TOST procedure showed statistical equivalence
between normal tissue and meningiomas (± δ =±1 . 5 )
for three reference genes: CASC3 (+0.87), IPO8 (+0.57)
and POP4 (+1.36). Those three genes were not normally
distributed in meningiomas (CASC3 (P-value = 0.002),
IPO8 (P-value < 0.0001) and POP4 (P-value = 0.0005).
After inclusion of the normal tissue group IPO8 and
POP4 remained not normally distributed.
Contribution of reference genes on expression levels of
target genes
The selection of a reference gene for normalisation of
qPCR can have a distinct influence on the expression
profile of target genes [29]. To show the influence of dif-
ferent reference genes on the determination of gene
expression levels, VEGFA expression levels in meningio-
mas and their control tissues were sequentially normal-
ized with the analyzed ten reference genes. The Ct values
for VEGFA were between 29 and 31. The expression
level of VEGFA was normalized to each single reference
gene as shown in Figure 3. The relative gene expression
level (RQ) of VEGFA was calculated relative to the ara-
chnoidea group (RQArachnoidea = 1). Subsequent bars
represented the different expression levels of VEGFA in
normal brain, dura and meningiomas normalized by
Figure 1 Expression levels of 32 candidate reference genes. Expression levels of 32 reference genes in four meningiomas, the malignant
meningioma cell line IOMM-Lee, normal brain, cerebral meninges and dura mater. Real-Time PCR cycle threshold numbers are shown (Ct value).
Box plots represent maximum and minimum values with median. Lower Ct values indicate higher gene expression.
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tained the ratio between brain, dura and meningioma
except IPO8 and CASC3. Normalization with IPO8 or
CASC3 showed significantly increased ratio for brain to
dura and brain to tumour.
Discussion
The requirement for distinct and reproducible results
from quantitative gene expression analysis is accurate
data normalization [23,24,29,30]. The application of an
inappropriate reference gene can lead to false experi-
mental conclusions [31-33]. Therefore one or more
reference need to be chosen dependent on used tissue
and experimental conditions.
T oo u rk n o w l e d g e ,t h i si st h ef i r s ts y s t e m a t i ca n a l y s i s
of average expression stability of reference genes in
meningiomas for data normalisation in qPCR experi-
ments. To evaluate the average expression stability four
analysis software programs (geNorm, NormFinder,
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Figure 2 Comprehensive gene stability of 32 candidate reference genes in meningiomas and control tissue. Geomean of ranking values
(y-axis) of 32 reference genes with their ranking from least to most stable gene expression (x-axis). Lower geomean values indicate more stable
gene expression.
Table 3 Ranking of ten candidate reference genes in
meningiomas and their control tissue based on average
expression stability value as calculated by Bestkeeper-1
and NormFinder
Rank Bestkeeper-1 NormFinder
Gene name Stability value Gene name Stability value
1 RPL37A 0.54 RPL37A 0.118
2 CASC3 0.54 EIF2B1 0.122
3 MRPL19 0.65 POP4 0.155
4 IPO8 0.66 MRPL19 0.163
5 POP4 0.70 PGK1 0.169
6 PPIA 0.73 PPIA 0.200
7 EIF2B1 0.74 GAPDH 0.286
8 PGK1 0.76 ACTB 0.287
9 GAPDH 0.83 CASC3 0.289
10 ACTB 1.00 IPO8 0.380
Table 4 Ranking of ten candidate reference genes in
meningiomas based on average expression stability
value as calculated by Bestkeeper-1 and NormFinder
Rank Bestkeeper-1 NormFinder
Gene name Stability value Gene name Stability value
1 CASC3 0.43 MRPL19 0.197
2 RPL37A 0.45 POP4 0.269
3 MRPL19 0.59 IPO8 0.277
4 IPO8 0.62 PPIA 0.312
5 PPIA 0.63 PGK1 0.332
6 POP4 0.63 EIF2B1 0.355
7 PGK1 0.67 GAPDH 0.386
8 EIF2B1 0.70 CASC3 0.388
9 GAPDH 0.75 RPL37A 0.447
10 ACTB 0.95 ACTB 0.521
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based on different algorithms were used. So far various
reference genes (GAPDH, ACTB, S18, TBP) were used
in qPCR experiments in meningiomas [11-21,34],
although GAPDH was mainly used for normalizations.
This study demonstrates that none of these reference
genes were ranked under the ten most stable genes of
32 analyzed reference genes. However GAPDH and
ACTB as the most used reference genes in meningioma
qPCR experiments were further analyzed. After reducing
the number of reference genes and increasing the num-
ber of samples both reference genes were considered
one of the least stable genes. Bestkeeper-1 considered
ACTB unsuitable as reference gene in meningiomas and
their control tissues.
Because there is so few data available for gene expres-
sion of reference genes in meningiomas a large number
of reference genes were screened. Using four randomly
chosen meningiomas, the malignant meningioma cell
line IOMM-Lee, pooled normal brain, cerebral meninges
and dura mater was sufficient to determine expression
levels of all reference genes as shown in Table 1.
Because the four algorithms use different approaches for
their rankings of the 32 reference genes, the ranking dif-
fered significantly making a selection of genes for
further investigation difficult. Using the integration tool
which weighs the ranking of each algorithm made the
selection easier and more comprehensible. The six most
stable reference genes according to the integration tool
(PGK1, RPL37A, POP4, MRPL19, IPO8 and CASC3)
were chosen for further analysis. Additionally PPIA and
EIF2B1 were selected. PPIAw a st h eh i g h e s tr a n k e d
gene, which displayed high expression levels. EIF2B1
was the most stable gene with low expression levels.
Because RPL30 is potentially co-regulated with RPL37A,
it was not chosen, so the outcome of the result would
not be affected.
For a more detailed analysis the remaining ten refer-
ence genes were analyzed using an increased number of
samples (ntotal =4 6w i t hn normal =1 1a n dn meningioma =
35) but a decreased number of software (NormFinder
and Bestkeeper-1). NormFinder was chosen because of
Table 5 Ranking of ten candidate reference genes in
normal control tissue based on average expression
stability value as calculated by Bestkeeper-1 and
NormFinder
Rank Bestkeeper-1 NormFinder
Gene name Stability value Gene name Stability value
1 EIF2B1 0.45 EIF2B1 0.306
2 RPL37A 0.56 RPL37A 0.318
3 PPIA 0.65 MRPL19 0.329
4 MRPL19 0.69 PPIA 0.404
5 ACTB 0.75 GAPDH 0.415
6 POP4 0.77 POP4 0.419
7 IPO8 0.82 CASC3 0.462
8 GAPDH 0.82 ACTB 0.542
9 CASC3 0.85 PGK1 0.590
10 PGK1 1.04 IPO8 0.621
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Figure 3 Contribution of reference gene selection to determination of target gene expression levels. Data is expressed as relative gene
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of variation between normal and cancer tissue. In con-
trast Bestkeeper-1 employs a pair-wise correlation analy-
sis and uses raw Ct values whereas NormFinder uses
transformed quantities. Also Bestkeeper-1 directly
includes qPCR efficiency.
Both algorithms considered RPL37A as the most suita-
ble reference gene for normalization in qPCR in meningio-
mas and their control tissue. The following ranking
differed significantly especially for CASC3, IPO8 and
EIF2B1. Bestkeeper-1 considered CASC3 as the most
stable genes in meningiomas, but ranked CASC3 only in
ninth place for normal control tissue. This led to a second
place in the combined ranking due to the higher number
of tumour samples. In contrast NormFinder ranked
EIF2B1 highest for normal control tissue and only in sixth
place in meningiomas. Because NormFinder weighs the
two subgroups, normal tissue versus meningiomas, the
ranking of the control tissue has more influence on the
combined ranking. This is also demonstrated with IPO8
and conversely with RPL37A. NormFinder ranks RPL37A
in meningiomas only in ninth place and in normal control
tissue in second place. But after including the variation
between those subgroups NormFinder displays RPL37A as
the most stable gene for both subgroups.
Considering the results of the normalization of
VEGFA against every single reference genes with signifi-
cantly altered results for CASC3 and IPO8, NormFinder
displays a more accurate ranking for meningiomas and
their control tissue.
Some researchers recommend the use of multiple refer-
ence genes for calculating a normalization factor [23].
NormFinder also determines the best combination of two
genes, when subgroups are included. For meningiomas
and their normal control tissue the combination is
RPL37A and EIF2B1.
Conclusions
In conclusion, the results from the current study demon-
strate that RPL37A is the most appropriate single refer-
ence gene for the normalization process of gene profiling
studies in meningiomas and their normal control tissue
arachnoidea, dura mater and normal brain. If a combina-
tion of reference genes is applicable RPL37A and EIF2B1
are most suitable. Additionally results from the current
s t u d yi n d i c a t et h a tw i d e l yu s e dG A P D Ha n dA C T Ba r e
both inappropriate reference genes for meningiomas.
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